What's Going On With BioCryst Stock After Earnings?
What's Going On With BioCryst Stock After Earnings?
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares are flat Monday after the company reported its fourth-quarter financial results before the opening bell.
BioCryst 制药公司（纳斯达克股票代码：BCRX）股价周一持平，此前该公司在开盘前公布了第四季度财务业绩。
The Details:
细节：
BioCryst reported quarterly losses of 28 cents per share, missing the analyst consensus estimate of losses of 24 cents by 16.67% and representing a 26.32% increase over losses of 38 cents per share from the same period last year.
BioCryst公布的季度亏损为每股28美分，比分析师普遍预期的24美分亏损高出16.67％，比去年同期每股亏损38美分增长26.32％。
The company reported quarterly sales of $93.4 million which beat the analyst consensus estimate of $90.01 million by 3.77% and is a 17.42% increase over sales of $79.55 million from the prior year's quarter.
该公司公布的季度销售额为9,340万美元，比分析师普遍预期的9,001万美元高出3.77％，比去年同期的7,955万美元的销售额增长了17.42％。
BioCryst sees fiscal year 2024 Orladeyo net revenue of between $380 million and $400 million. The company said that it expects an operating profit in 2024 and to be approaching positive earnings per share and positive cash flow in the second half of 2025.
BioCryst预计，奥拉迪奥2024财年的净收入在3.8亿美元至4亿美元之间。该公司表示，预计2024年将实现营业利润，并将在2025年下半年接近正每股收益和正现金流。
"The impressive growth we are seeing with ORLADEYO has put us in a position to accelerate our path to profitability while continuing to invest in our diverse pipeline of first-in-class or best-in-class molecules that we believe will deliver our next marketed product," said Jon Stonehouse, CEO of BioCryst.
BioCryst首席执行官乔恩·斯通豪斯表示：“我们在ORLADEYO看到的惊人增长使我们能够加快盈利之路，同时继续投资于我们多样化的同类首创或同类最佳分子产品线，我们认为这些分子将提供我们的下一个上市产品。”
BioCryst said the total number of U.S. patients on paid or long-term free product reached 1,104 at the end of the fourth quarter and net U.S. patient growth totaled 321 in 2023.
BioCryst表示，在第四季度末，使用付费或长期免费产品的美国患者总数达到1,104人，2023年美国患者净增长总数为321人。
Related News: Wedbush's Dan Ives Says 'AI Party Just Starting'
相关新闻： Wedbush 的丹·艾夫斯说 “人工智能派对才刚刚开始”
Is BCRX A Good Stock To Buy?
BCRX 是一只值得买入的好股票吗？
Wall Street analysts view BioCryst Pharma on the whole as a Buy, given the history of coverage over the past three months. Serge Belanger from Needham in BioCryst Pharma is the most optimistic.
鉴于过去三个月的报道历史，华尔街分析师将BioCryst Pharma总体上视为买入。来自尼德姆的BioCryst Pharma的塞尔吉·贝兰格是最乐观的。
But looking at how the market as a whole thinks of the stock, you can reference historical price action for views on whether investors feel strongly about the stock one way or another. In the past 3 months, BioCryst Pharma rose 8.74%, which indicates that opinion improved on the business and how attractive it is to own based on either its stock price, or underlying fundamentals, like revenue, which rose 17.42% over the past year.
但是，从整个市场对股票的看法来看，你可以参考历史价格走势，了解投资者是否以某种方式对股票有强烈的看法。在过去的3个月中，BioCryst Pharma上涨了8.74％，这表明人们对该业务的看法有所改善，以及根据其股价或收入等基本面（在过去一年中增长了17.42％），拥有该业务的吸引力有所改善。
A complete overview of how Wall Street views individual stocks is available here, while real time updates on the latest analyst actions will be delivered via Benzinga PRO. Try it for free.
华尔街如何看待个股的完整概述可在此处获得，而分析师最新行动的实时更新将通过Benzinga PRO提供。免费试用。
BCRX Price Action: According to Benzinga Pro, BioCryst shares are up 0.49% at $5.738 at the time of publication.
BCRX价格走势：根据Benzinga Pro的数据，BioCryst的股价在发布时上涨0.49％，至5.738美元。
Image: Volodymyr Hryshchenko from Unsplash
图片：沃洛迪米尔·赫里申科 来自 Unslash